InVitae Corp (NYSE:NVTA) COO E Lee Bendekgey sold 21,265 shares of the business’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $25.29, for a total transaction of $537,791.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of NYSE:NVTA traded down $1.13 on Thursday, hitting $25.32. The stock had a trading volume of 67,533 shares, compared to its average volume of 2,439,517. InVitae Corp has a twelve month low of $9.04 and a twelve month high of $28.75. The company has a debt-to-equity ratio of 0.36, a quick ratio of 7.18 and a current ratio of 7.18. The firm’s 50 day moving average price is $24.83 and its 200-day moving average price is $21.71. The company has a market capitalization of $2.45 billion, a price-to-earnings ratio of -13.07 and a beta of 2.53.
InVitae (NYSE:NVTA) last issued its earnings results on Tuesday, August 6th. The medical research company reported ($0.54) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.06). InVitae had a negative net margin of 83.69% and a negative return on equity of 58.48%. The firm had revenue of $53.48 million during the quarter, compared to analyst estimates of $50.17 million. During the same quarter in the prior year, the firm posted ($0.47) EPS. The firm’s revenue for the quarter was up 43.3% on a year-over-year basis. As a group, sell-side analysts predict that InVitae Corp will post -2.11 EPS for the current year.
Several equities research analysts have issued reports on the stock. Zacks Investment Research lowered shares of InVitae from a “buy” rating to a “hold” rating in a report on Friday, April 26th. Oppenheimer set a $34.00 price target on shares of InVitae and gave the company a “buy” rating in a report on Wednesday, August 7th. Chardan Capital restated a “buy” rating and issued a $30.00 target price on shares of InVitae in a research note on Tuesday, June 11th. Benchmark restated a “buy” rating and issued a $28.00 target price (up previously from $26.00) on shares of InVitae in a research note on Wednesday, August 7th. Finally, Leerink Swann set a $31.00 target price on shares of InVitae and gave the company a “buy” rating in a research note on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $28.17.
Several large investors have recently modified their holdings of the company. Parallel Advisors LLC acquired a new position in InVitae during the 2nd quarter worth about $25,000. PNC Financial Services Group Inc. acquired a new position in InVitae during the 1st quarter worth about $26,000. Certified Advisory Corp acquired a new position in InVitae during the 1st quarter worth about $30,000. First Quadrant L P CA acquired a new position in InVitae during the 2nd quarter worth about $36,000. Finally, Signaturefd LLC acquired a new position in InVitae during the 1st quarter worth about $47,000. Institutional investors own 87.51% of the company’s stock.
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.
Read More: Equity Income
Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.